Sumitomo Dainippon Pharma Annual Report 2017
91/102

Millions of yenThousands of U.S. dollars$ 564,625$ 564,625¥ 63,238¥ 63,238Purchase consideration (cash)Acquisition costMillions of yenThousands of U.S. dollars$ 622,196¥ 69,686In-process research and developmentEstimated useful lifeMillions of yenThousands of U.S. dollars$ 9,152622,991632,14375,1433,580$ 78,723¥ 1,02569,77570,8008,416401¥ 8,817Current assetsFixed assetsTotal assetsCurrent liabilitiesLong-term liabilitiesTotal liabilities3. Date of business combinationOctober 21, 2016 (U.S. Eastern Standard Time)4. Legal form of business combinationAcquisition of shares for cash consideration5. Name of the company after combinationSunovion CNS Development Canada ULC.6. Ratio of voting rights acquired100%7. Main grounds for reaching a decision on the acquiring companyIt is because Sunovion CNS Development Canada ULC(old company) acquired shares of Cynapsus in exchange for cash. On the closing day, a new company with the same name was established with amalgamation of Cynapsus Therapeutics Inc. and Sunovion CNS Development Canada ULC (old company).b. Period of performance of the acquired company included in the consolidated nancial statementsFrom October 21, 2016 to March 31, 2017c. Acquisition cost and consideration of the acquired company and the breakdown thereofd. Major acquisition-related costs and amountsAdvisory fees and others ¥681 million ($6,080 thousand)e. Amount of goodwill, reason for recognition, amortization method and amortization period1. Amount of goodwill: ¥1,255 million ($11,205 thousand)2. Reason for recognition: As the acquisition cost exceeded the net amount of assets acquired and liabilities assumed, the difference has been posted as goodwill.3. Amortization method and amortization period: Straight-line method over 20 years4. The amount of goodwill is a temporarily calculated amount.f. Total assets acquired and liabilities assumed on the date of business combination and the main breakdown thereofg. Amount allocated to intangible xed assets other than goodwill and amortization period for the entity is as follows:h. Allocation of acquisition costThe allocation of acquisition cost was not completed at the end of the consolidated scal year ended March 31, 2017 and the cost is recognized based on reasonable information available at that point of time.AmountAmortization periodDescriptionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201790

元のページ  ../index.html#91

このブックを見る